Clinical Study
Influence of Anti-TNF and Disease Modifying Antirheumatic Drugs Therapy on Pulmonary Forced Vital Capacity Associated to Ankylosing Spondylitis: A 2-Year Follow-Up Observational Study
Table 3
Primary outcomes. Comparison in absolute changes on pulmonary function tests between baseline and 24 months in DMARDs group versus anti-TNF+DMARDs group.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
DMARDs, disease modifying antirheumatic drugs; anti-TNF + DMARDs, antitumor necrosis factor + DMARDs; FVC%, forced vital capacity; FEV1%, forced expiratory volume in 1 second. Quantitative variables are shown as median and ranges; qualitative variables are shown in frequencies (%). Absolute change is obtained from the differences at 24 months versus baseline. values for Δ absolute change: comparison between groups of differences in absolute changes at baseline and 24 months. Comparison of the absolute change between groups at 24 month was performed with Mann-Whitney test. Fisher exact test was used to compare the proportion of patients who achieve changes of the cut-off point in FVC%. |